FDA Clearance Tracker · P200010-S021
Guardant360 CDx
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Sep 25, 2025
Approved
Time to decision
325 days
Received Nov 4, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P200010-S021
- Device name
- Guardant360 CDx
- Applicant
- Guardant Health, Inc.
- Applicant location
- Redwood City, CA
- Received
- Nov 4, 2024
- Decided
- Sep 25, 2025
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P200010
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for expanding the indications for use to include the companion diagnostic claim to identify breast cancer patients with specific ESR1 mutations for treatment with INLURIYO (imlunestrant).
Source documents
Other decisions for Guardant Health, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250027 · Decided May 19, 2026 · 292 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360 CDxPMA supplement
P200010-S026 · Decided Jan 15, 2026 · 176 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- ShieldPMA
P230009 · Decided Jul 26, 2024 · 504 days after receipt
Device type: System, colorectal neoplasia, DNA methylation and hemoglobin detection (PHP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.